92Bio doses the first patient in a Phase 1 trial with NTB-928, a T cell engager it reclaimed from Amgen after the company shelved the program.
Ben Buelow, 92Bio CEO
July 1, 2026 09:30 AM EDTUpdated 09:43 AM
StartupsR&D
A discarded Amgen T cell engager comes back to life at its California creator, 92Bio
Kyle LaHucik
On Thursday, the American Society of Gene & Cell Therapy (ASGCT) and the Orphan Therapeutics Accelerator (OTXL) debuted a joint…
92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer
The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers,…
San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life…
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout
92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer
Orca Bio makes a splash with FDA approval for cell therapy Tregzi. Could an IPO come next?
FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers
After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL
FDA approves Orca Bio’s T cell therapy for blood cancer patients
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
